Bibliografia UJ CM




Zapytanie: LANCET HAEMATOLOGY
Liczba odnalezionych rekordów: 10



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wersja do druku | | | Nowe wyszukiwanie
1/10
Cristina Nanni, Carsten Kobe, Bettina Baeßler, Christian Baues, Ronald Boellaard, Peter Borchmann, Andreas Buck, Irene Buvat, Björn Chapuy, Bruce D. Cheson, Robert Chrzan, Ann-Segolene Cottereau, Ulrich Dührsen, Live Eikenes, Martin Hutchings, Wojciech Jurczak, Françoise Kraeber-Bodéré, Egesta Lopci, Stefano Luminari, Steven MacLennan, N. George Mikhaeel, Marcel Nijland, Paula Rodríguez-Otero, Giorgio Treglia, Nadia Withofs, Elena Zamagni, Pier Luigi Zinzani, Josée M. Zijlstra, Ken Herrmann, Jolanta Kunikowska.
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations : molecular imaging and therapy in haematological tumours
Lancet. Haematology
2023 : Vol. 10, nr 5, s.e367-e381, bibliogr. 42 poz., sum.
Autor korespondencyjny: Cristina Nanni
e-ISSN: 2352-3026

AZ
POG
AIF
IF: 24.700
Adres url:
Streszczenie w PubMed:
DOI:
2/10
Asya Agulnik.
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war
Lancet. Haematology
2022 : Vol. 9, nr 9, s. e645-e647, bibliogr.
Autor korespondencyjny: Asya Agulnik
SAFER Ukraine Collaborative

e-ISSN: 2352-3026

AZ
AIF
IF: 24.700
Adres url:
Streszczenie w PubMed:
3/10
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV) : a randomised, non-inferiority, phase 3 trial and its extension study.
Lancet. Haematology
2020 : Vol. 7, nr 3, s. e196-e208, sum.
Autor korespondencyjny: Heinz Gisslinger.
e-ISSN: 2352-3026

AZ
ORG
AIF
IF: 18.959
Adres url:
Streszczenie w PubMed:
DOI:
4/10
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigon, Andrzej Hellmann, Bryone Kuss, David D.F. Ma, Fatih Demirkan, Munci Yagci, Netanel A. Horowitz, Paula Marlton, Raul Cordoba, Tomasz Wrobel, Daniela Buglio, Michael Streit, Brendan P. Hodkinson, Michael Schaffer, John Alvarez, Rob Ceulemans, Sriram Balasubramanian, Jan de Jong, Shean-sheng Wang, Nele Fourneau, Wojciech Jurczak.
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Lancet. Haematology
2019 : Vol. 6, nr 2, s. e67-e78, bibliogr., abstr.
Autor korespondencyjny: AnasYounes.
p-ISSN: 2352-3026

AZ
ORG
AIF
IF: 10.406
Adres url:
Streszczenie w PubMed:
DOI:
5/10
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, H. Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Anne Lennard, Jose Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zharvid, Eduardo Yanez Ruiz, Marek Trneny, Leslie Popplewall, Bertrand Coiffier, Christian Buske, Won-Seog Kim, Sang Joon Lee, Sung Young Lee, Jun Ju Bae, Larry W. Kwak.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Lancet. Haematology
2018 : Vol. 5, nr 11, s. e543-e553, il., bibliogr.
Autor korespondencyjny: Larry W. Kwak.
p-ISSN: 2352-3026

AZ
ORG
AIF
IF: 11.990
Adres url:
Streszczenie w PubMed:
DOI:
6/10
Won Seog Kim, Christian Buske, Michinori Ogura, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José-Ángel Hernández-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajinish Nagarkar, Dzhelil Osmanov, Larry W. Kwak, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Bertrand Coiffier.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
Lancet. Haematology
2017 : Vol. 4, nr 8, s. e362-e373
Autor korespondencyjny: Bertrand Coiffier.
p-ISSN: 2352-3026

AZ
ORG
AIF
IF: 10.698
Adres url:
Streszczenie w PubMed:
DOI:
7/10
Wojciech Jurczak, Arnold G. Vulto, Jutta Amersdorffer, Won S. Kim, Bertrand Coiffier.
Research on Biosimilars: pivotal trials and principles.
Lancet. Haematology
2017 : Vol. 4, nr 9, s. e409-e410
Autor korespondencyjny: Bertrand Coiffier.
p-ISSN: 2352-3026

LR
AIF
IF: 10.698
Adres url:
Streszczenie w PubMed:
DOI:
8/10
Wojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty, Eduardo Munhoz, Maria Asunción Echeveste, Pratyush Giri, Nelson Castro, Juliana Pereira, Luiza Akria, Sergey Alexeev, Eugeniy Osmanov, Peijuan Zhu, Siyka Alexandrova, Angela Zubel, Olof Harlin, Jutta Amersdorffer.
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Lancet. Haematology
2017 : Vol. 4, nr 8, s. e350-e361
Autor korespondencyjny: Wojciech Jurczak.
p-ISSN: 2352-3026

AZ
ORG
AIF
IF: 10.698
Adres url:
Streszczenie w PubMed:
DOI:
9/10
Anetta Undas.
Statins in prevention of venous thromboembolism.
Lancet. Haematology
2017 : Vol. 4, nr 2, s. e61-e62
Autor korespondencyjny: Anetta Undas.
p-ISSN: 2352-3026

KO
AIF
IF: 10.698
Adres url:
Streszczenie w PubMed:
DOI:
10/10
Jorge E. Cortes, Carmino Antonio De Souza, Manuel Ayala, Jose Luis Lopez, Eduardo Bullorsky, Sandip Shah, Xiaojun Huang, K. Govind Babu, Kudrat Abdulkadyrov, José Salvador Rodrigues de Oliveira,, Zhi-Xiang Shen, Tomasz Sacha, Israel Bendit, Zhizhou Liang, Tina Owugah, Tomasz Szczudlo, Sadhvi Khanna, Rafik Fellague-Chebra, Philipp D. le Coutre.
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Lancet. Haematology
2016 : Vol. 3, nr 12, s. e581-e591
p-ISSN: 2352-3026
e-ISSN: 2352-3026

AZ
ORG
AIF
IF: 7.123
Adres url:
Streszczenie w PubMed:
DOI:
  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ